Reducing selection bias in case-control studies from rare disease registries
Open Access
- 12 September 2011
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 61
Abstract
Background: In clinical research of rare diseases, where small patient numbers and disease heterogeneity limit study design options, registries are a valuable resource for demographic and outcome information. However, in contrast to prospective, randomized clinical trials, the observational design of registries is prone to introduce selection bias and negatively impact the validity of data analyses. The objective of the study was to demonstrate the utility of case-control matching and the risk-set method in order to control bias in data from a rare disease registry. Data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry were used as an example. Methods: A case-control matching analysis using the risk-set method was conducted to identify two groups of patients with type 1 Gaucher disease in the ICGG Gaucher Registry: patients with avascular osteonecrosis (AVN) and those without AVN. The frequency distributions of gender, decade of birth, treatment status, and splenectomy status were presented for cases and controls before and after matching. Odds ratios (and 95% confidence intervals) were calculated for each variable before and after matching. Results: The application of case-control matching methodology results in cohorts of cases (i.e., patients with AVN) and controls (i.e., patients without AVN) who have comparable distributions for four common parameters used in subject selection: gender, year of birth (age), treatment status, and splenectomy status. Matching resulted in odds ratios of approximately 1.00, indicating no bias. Conclusions: We demonstrated bias in case-control selection in subjects from a prototype rare disease registry and used case-control matching to minimize this bias. Therefore, this approach appears useful to study cohorts of heterogeneous patients in rare disease registries.Keywords
This publication has 22 references indexed in Scilit:
- Long-term risk of chronic kidney disease in unilateral multicystic dysplastic kidneyPediatric Nephrology, 2011
- A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imigluceraseAmerican Journal of Hematology, 2008
- Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringJournal of Inherited Metabolic Disease, 2008
- Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among Hematologists–Oncologists and an opportunity for early diagnosis and interventionAmerican Journal of Hematology, 2007
- Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher DiseaseJournal of Bone and Mineral Research, 2007
- The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at DiagnosisArchives of Pediatrics & Adolescent Medicine, 2006
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- The Gaucher RegistryArchives of internal medicine (1960), 2000
- Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant SourcesAnnals of Internal Medicine, 1995
- Simulation Study of Confounder-Selection StrategiesAmerican Journal of Epidemiology, 1993